Operation Warp Speed Could Shape Up to Be an $18 Billion Bargain

Oct. 29, 2020, 8:00 AM

On a late August day in an industrial corner of Baltimore that had been mostly silenced by the pandemic, a red-brick manufacturing plant was buzzing with activity. Deep in the building, in a zone called Area 3, the stainless steel shell of a bioreactor lay on its side, having just arrived from Massachusetts. Employees had begun the task of making the bioreactor operational. Within weeks it would be the center of a production line for coronavirus vaccines.

Megaphone.fm: Here. It. Comes. by Listen to the Story

When the owner of the plant, Emergent BioSolutions Inc., ordered the bioreactor, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.